Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
F-box proteins, as substrates for S phase kinase-associated protein 1 (SKP1)-cullin 1 (CUL1)-F-box protein (SCF) ubiquitin ligase complexes, mediate the degradation of a large number of regulatory proteins involved in cancer processes. In this study, we found that
F-box only protein 2
(
FBXO2
) was up-regulated in 21
endometrial carcinoma
(EC) samples compared with five normal endometrium samples based on our Fudan cohort RNA-sequencing. The increased
FBXO2
expression was associated with tumor stage, tumor grade, and histologic tumor type, and poor prognosis based on The Cancer Genome Atlas (TCGA) database.
FBXO2
knockdown inhibited EC cell proliferation, and
FBXO2
overexpression promoted the parental cell phenotype
in vivo
and
in vitro
. Fibrillin1 (FBN1) was also identified as a substrate for
FBXO2
using a ubiquitination-proteome approach. In addition, promotion of EC proliferation by
FBXO2
was regulated by specific proteins of the cell cycle (CDK4, CyclinD1, CyclinD2, and CyclinA1) and the autophagy signaling pathway (ATG4A and ATG4D) based on RNA sequencing (RNA-seq). We concluded that
FBXO2
acts as an E3 ligase that targets FBN1 for ubiquitin-dependent degradation, so as to promote EC proliferation by regulating the cell cycle and the autophagy signaling pathway. Targeting
FBXO2
may represent a potential therapeutic target for EC.
...
PMID:FBXO2 Promotes Proliferation of Endometrial Cancer by Ubiquitin-Mediated Degradation of FBN1 in the Regulation of the Cell Cycle and the Autophagy Pathway. 3298 35